COVID-19: Will Gilead price its drug for public good or company profit?
REUTERS: Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with COVID-19.
The drug manufacturer earned notoriety less than a decade ago, when it introduced a treatment that essentially cured hepatitis C at …
Go to Source